Yaxin Chen

Yaxin Chen

Auto-generated profile, based on publicly available information

Yaxin Chen

Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Research Center, West China Hospital, Department of Respiratory and Critical Care Medicine, Sichuan University , Chengdu 610041

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
PDF file
YLYao Lin
Yao Lin
JLJingyi Li
Jingyi Li
SLShuaiyi Liang
Shuaiyi Liang
YCYaxin Chen
Yaxin Chen
YLYueqi Li
Yueqi Li
SASanqi An
Sanqi An
As the most abundant messenger RNA (mRNA) modification, N6-methyladenosine (m6A) plays a crucial role in RNA fate, impacting cellular and physiological processes in various tumor types. However, our understanding of the role of the m6A methylome in tumor heterogeneity remains limited. Herein, we collected and analyzed m6A methylomes across nine human tissues from 97 m6A sequencing (m6A-seq) and RNA sequencing (RNA-seq) samples. Our findings demonstrate that m6A exhibits different heterogeneity in most tumor tissues compared to normal tissues, which contributes to the diverse clinical outcomes in different cancer types. We also found that the cancer type-specific m6A level regulated the expression of different cancer-related genes in distinct cancer types. Utilizing a novel and reliable method called “m6A-express”, we predicted m6A-regulated genes and revealed that cancer type-specific m6A-regulated genes contributed to the prognosis, tumor origin, and infiltration level of immune cells in diverse patient populations. Furthermore, we identified cell-specific m6A regulators that regulate cancer-specific m6A and constructed a regulatory network. Experimental validation was performed, confirming that the cell-specific m6A regulator CAPRIN1 controls the m6A level of TP53. Overall, our work reveals the clinical relevance of m6A in various tumor tissues and explains how such heterogeneity is established. These results further suggest the potential of m6A in cancer precision medicine for patients with different cancer types.

13 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYao Lin
Yao Lin
JLJingyi Li
Jingyi Li
SLShuaiyi Liang
Shuaiyi Liang
YCYaxin Chen
Yaxin Chen
YLYueqi Li
Yueqi Li
SASanqi An
Sanqi An
As the most abundant mRNA modification in mRNA, N 6 -methyladenosine (m 6 A) plays a crucial role in RNA fate, impacting cellular and physiological processes in various tumor types. However, our understanding of the function and role of the m 6 A methylome in tumor heterogeneity remains limited. Herein, we collected and analyzed m 6 A methylomes across nine human tissues from 97 m 6 A-seq and RNA-seq samples. Our findings demonstrate that m 6 A exhibits different heterogeneity in most tumor tissues compared to normal tissues, which contributes to the diverse clinical outcomes in different cancer types. We also found that the cancer type-specific m 6 A level regulated the expression of different cancer-related genes in distinct cancer types. Utilizing a novel and reliable method called “m 6 A-express”, we predicted m 6 A– regulated genes and revealed that cancer type-specific m 6 A-regulated genes contributed to the prognosis, tumor origin and infiltration level of immune cells in diverse patient populations. Furthermore, we identified cell-specific m 6 A regulators that regulate cancer-specific m 6 A and constructed a regulatory network. Experimental validation was performed, confirming that the cell-specific m 6 A regulator CAPRIN1 controls the m 6 A level of TP53 . Overall, our work reveals the clinical relevance of m 6 A in various tumor tissues and explains how such heterogeneity is established. These results further suggest the potential of m 6 A for cancer precision medicine for patients with different cancer types.